Hims & Hers Health Inc. (HIMS) has emerged as a standout in the telehealth sector.
The company shares skyrocketed as much as 18% following the announcement of President-elect Donald Trump’s nomination of Dr. Marty Makary to lead the Food and Drug Administration (FDA). Dr. Makary’s ties to compounded GLP-1 drugs—a key revenue driver for Hims—signal potential regulatory tailwinds for the company, even as it navigates a complex and evolving landscape.
Regulatory Shifts Spark Investor Optimism
Hims & Hers’ fortunes took a sharp turn after Hunterbrook Media highlighted Dr. Makary’s role as an executive at Sesame Inc., another telehealth provider offering compounded GLP-1 weight-loss drugs. This connection positions Hims & Hers as a potential beneficiary of a more lenient regulatory environment under Makary’s leadership, should he be confirmed.
The company’s compounded semaglutide products have been a hot topic this year. While these drugs are not FDA-approved, they remain permissible due to shortages of branded versions from industry giants Eli Lilly and Novo Nordisk. Recent court filings revealing the FDA’s delay in removing tirzepatide, another GLP-1 drug, from the shortage list have further bolstered Hims’ outlook.
Hims & Hers, which has rallied over 200% year-to-date, is now on track for its best annual performance since going public. However, the regulatory landscape remains uncertain, with the FDA’s pending decisions likely to shape the future of GLP-1 compounding.
Hims & Hers’ fortunes took a sharp turn after Hunterbrook Media highlighted Dr. Makary’s role as an executive at Sesame Inc., another telehealth provider offering compounded GLP-1 weight-loss drugs. This connection positions Hims & Hers as a potential beneficiary of a more lenient regulatory environment under Makary’s leadership, should he be confirmed.
The company’s compounded semaglutide products have been a hot topic this year. While these drugs are not FDA-approved, they remain permissible due to shortages of branded versions from industry giants Eli Lilly and Novo Nordisk. Recent court filings revealing the FDA’s delay in removing tirzepatide, another GLP-1 drug, from the shortage list have further bolstered Hims’ outlook.
Hims & Hers, which has rallied over 200% year-to-date, is now on track for its best annual performance since going public. However, the regulatory landscape remains uncertain, with the FDA’s pending decisions likely to shape the future of GLP-1 compounding.
A Growing Market, But Challenges Remain
Hims & Hers’ rapid growth extends beyond GLP-1 offerings. The telehealth platform, which connects consumers with licensed healthcare professionals, has seen revenue surge 22.3% annually, outpacing the broader U.S. market. The company reported $1.24 billion in online retail revenue and a net income of $75.59 million in Q3 2024, signaling profitability and strong operational momentum.
Despite these achievements, Wall Street remains cautious. More than half of analysts rate HIMS as a hold or sell, citing concerns about shareholder dilution and potential regulatory headwinds. Furthermore, competitive pressures from peers like Sesame and traditional pharmaceutical companies loom large.
Michael Cherny of BofA Securities noted that while Makary’s nomination is an “incrementally positive” development, the broader GLP-1 opportunity remains unpredictable. The FDA’s decision on tirzepatide and its stance on compounding will likely have far-reaching implications for Hims & Hers and the telehealth sector as a whole.
Hims & Hers’ rapid growth extends beyond GLP-1 offerings. The telehealth platform, which connects consumers with licensed healthcare professionals, has seen revenue surge 22.3% annually, outpacing the broader U.S. market. The company reported $1.24 billion in online retail revenue and a net income of $75.59 million in Q3 2024, signaling profitability and strong operational momentum.
Despite these achievements, Wall Street remains cautious. More than half of analysts rate HIMS as a hold or sell, citing concerns about shareholder dilution and potential regulatory headwinds. Furthermore, competitive pressures from peers like Sesame and traditional pharmaceutical companies loom large.
Michael Cherny of BofA Securities noted that while Makary’s nomination is an “incrementally positive” development, the broader GLP-1 opportunity remains unpredictable. The FDA’s decision on tirzepatide and its stance on compounding will likely have far-reaching implications for Hims & Hers and the telehealth sector as a whole.
Balancing Growth and Risk
As Hims & Hers charts its path forward, the company has signaled plans to expand its platform through acquisitions and strategic partnerships. Insider buying in recent quarters also reflects confidence in its long-term prospects, despite short-term uncertainties.
The stock’s surge reflects optimism over regulatory shifts, but investors remain mindful of the risks. With Makary’s nomination raising hopes for a favorable FDA environment and GLP-1 shortages keeping demand high, Hims & Hers has an opportunity to solidify its market position. However, the company’s ability to navigate regulatory hurdles and fend off competition will be crucial to sustaining its upward trajectory.
Conclusion
Hims & Hers Health finds itself at a pivotal moment, buoyed by regulatory optimism and robust revenue growth. While challenges persist, the company’s strategic positioning and adaptability could enable it to capitalize on the shifting telehealth landscape. For investors, the stakes are high—but so is the potential reward.
As Hims & Hers charts its path forward, the company has signaled plans to expand its platform through acquisitions and strategic partnerships. Insider buying in recent quarters also reflects confidence in its long-term prospects, despite short-term uncertainties.
The stock’s surge reflects optimism over regulatory shifts, but investors remain mindful of the risks. With Makary’s nomination raising hopes for a favorable FDA environment and GLP-1 shortages keeping demand high, Hims & Hers has an opportunity to solidify its market position. However, the company’s ability to navigate regulatory hurdles and fend off competition will be crucial to sustaining its upward trajectory.
Conclusion
Hims & Hers Health finds itself at a pivotal moment, buoyed by regulatory optimism and robust revenue growth. While challenges persist, the company’s strategic positioning and adaptability could enable it to capitalize on the shifting telehealth landscape. For investors, the stakes are high—but so is the potential reward.
Considering a $1,000 investment in these companies?
Our team at Stock Investor carefully curated a list of top stocks with the potential for significant returns, suitable for beginners and seasoned investors alike who are eager to learn a trade and unearth the best stocks to buy. Though not featured in this article, these selected stocks could be game-changers in the future.For those seeking dynamic trading experiences, consider joining our Swing Trade Alerts, Option Income Alert, or our Trading Room. Take advantage of our special offer today, starting at just $1 in the first month.
Unlock the secrets of Smart Money
Explore how billionaires and institutions are influencing the market. Follow their every move with DarkOption Flow and stay updated on essential market insights. Begin your journey to informed investing today!
Education
And if you're a fan of Invest opedia, you'll appreciate what we offer at SharperTrades even more. Explore our comprehensive option trading course and technical trading course, where you can learn trading, analyze stocks, delve into chart patterns for stocks, and gain invaluable insights for making the best company investments.
Unlock Your Stock Market Edge with SharperTrades. Dive into powerful trading tools, learn a trade, and receive expert guidance. Stay up-to-date with regular market updates. Learn trading, basics of investing, and how to pick the best stocks to buy. Whether you're a beginner or seasoned investor and trader, we've got you covered. Get started for free, today!